Targeted pharmacological treatment of autism spectrum disorders: Fragile X and Rett syndromes

Frontiers in Cellular Neuroscience

Volumn 9, Issue FEB, 2015, Pages

  Hansen, Wang ^a   Sandipan, Pati ^b   Lucas, Pozzo Miller ^c   Doering, Laurie C ^d  

^a UNIVERSITY OF TORONTO   (Canada)

^b University of Alabama at Birmingham   (United States)

^c University of Alabama at Birmingham   (United States)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

Autism spectrum disorders; FMRP; Fragile X syndrome; MeCP2; Pharmacotherapy; Rett syndrome; Synaptic deficits; Treatment

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; ACAMPROSATE; AMPA RECEPTOR; ARBACLOFEN; BASIMGLURANT; BRAIN DERIVED NEUROTROPHIC FACTOR; CANNABINOID RECEPTOR; DOPAMINE RECEPTOR; FENOBAM; GANAXOLONE; GLYCOGEN SYNTHASE KINASE 3; ION CHANNEL; LITHIUM; MAMMALIAN TARGET OF RAPAMYCIN; MAVOGLURANT; MEMANTINE; METABOTROPIC RECEPTOR; MEVINOLIN; MINOCYCLINE; MITOGEN ACTIVATED PROTEIN KINASE; MONOAMINE; MUSCARINIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OXYTOCIN; OXYTOCIN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; SEROTONIN RECEPTOR; SOMATOMEDIN; UNCLASSIFIED DRUG;

ARTICLE; AUTISM; FRAGILE X SYNDROME; GENE MUTATION; HUMAN; LONG TERM DEPRESSION; MITOCHONDRION; MOLECULARLY TARGETED THERAPY; RETT SYNDROME;

EID: 84925070978     PISSN: 16625102     EISSN: None     Source Type: Journal    
DOI: 10.3389/fncel.2015.00055     Document Type: Article

References (322)

1. Abdala, A. P., Dutschmann, M., Bissonnette, J. M., and Paton, J. F. (2010). Correction of respiratory disorders in a mouse model of Rett syndrome. Proc. Natl. Acad. Sci. U S A 107, 18208-18213. doi: 10.1073/pnas.1012104107.
2. Abdala, A. P., Lioy, D. T., Garg, S. K., Knopp, S. J., Paton, J. F., and Bissonnette, J. M. (2014). Effect of Sarizotan, a 5-HT1a and D2-like receptor agonist, on respiration in three mouse models of Rett syndrome. Am. J. Respir. Cell Mol. Biol. 50, 1031-1039. doi: 10.1165/rcmb.2013-0372OC.
3. Abekhoukh, S., and Bardoni, B. (2014). CYFIP family proteins between autism and intellectual disability: links with Fragile X syndrome. Front. Cell. Neurosci. 8:81. doi: 10.3389/fncel.2014.00081.
4. Amir, R. E., Van den Veyver, I. B., Wan, M., Tran, C. Q., Francke, U., and Zoghbi, H. Y. (1999). Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 23, 185-188. doi: 10.1038/13810.
5. Anagnostou, E. (2012). Translational medicine: mice and men show the way. Nature 491, 196-197. doi: 10.1038/491196a.
6. Anagnostou, E., Soorya, L., Brian, J., Dupuis, A., Mankad, D., Smile, S., et al. (2014a). Intranasal oxytocin in the treatment of autism spectrum disorders: a review of literature and early safety and efficacy data in youth. Brain Res. 1580, 188-198. doi: 10.1016/j.brainres.2014.01.049..
7. Anagnostou, E., Zwaigenbaum, L., Szatmari, P., Fombonne, E., Fernandez, B. A., Woodbury-Smith, M., et al. (2014b). Autism spectrum disorder: advances in evidence-based practice. CMAJ 186, 509-519. doi: 10.1503/cmaj.121756.
8. Andari, E., Duhamel, J. R., Zalla, T., Herbrecht, E., Leboyer, M., and Sirigu, A. (2010). Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. Proc. Natl. Acad. Sci. U S A 107, 4389-4394. doi: 10.1073/pnas.0910249107.
9. Auerbach, B. D., Osterweil, E. K., and Bear, M. F. (2011). Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature 480, 63-68. doi: 10.1038/nature10658.
10. Ausió, J., de Paz, A. M., and Esteller, M. (2014). MeCP2: the long trip from a chromatin protein to neurological disorders. Trends Mol. Med. 20, 487-498. doi: 10.1016/j.molmed.2014.03.004.
11. Banerjee, S., Riordan, M., and Bhat, M. A. (2014). Genetic aspects of autism spectrum disorders: insights from animal models. Front. Cell. Neurosci. 8:58. doi: 10.3389/fncel.2014.00058.
12. Bassell, G. J., and Warren, S. T. (2008). Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron 60, 201-214. doi: 10.1016/j.neuron.2008.10.004.
13. Bear, M. F., Huber, K. M., and Warren, S. T. (2004). The mGluR theory of fragile X mental retardation. Trends Neurosci. 27, 370-377. doi: 10.1016/j.tins.2004.04.009.
14. Ben-Ari, Y., Khalilov, I., Kahle, K. T., and Cherubini, E. (2012). The GABA excitatory/inhibitory shift in brain maturation and neurological disorders. Neuroscientist 18, 467-486. doi: 10.1177/1073858412438697.
15. Berry-Kravis, E. (2014). Mechanism-based treatments in neurodevelopmental disorders: fragile X syndrome.Pediatr. Neurol. 50, 297-302. doi: 10.1016/j.pediatrneurol.2013.12.001.
16. Berry-Kravis, E., Hessl, D., Abbeduto, L., Reiss, A. L., Beckel-Mitchener, A., and Urv, T. K. (2013). Outcome measures for clinical trials in fragile X syndrome. J. Dev. Behav. Pediatr. 34, 508-522. doi: 10.1097/DBP.0b013e31829d1f20.
17. Berry-Kravis, E., Hessl, D., Coffey, S., Hervey, C., Schneider, A., Yuhas, J., et al. (2009). A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J. Med. Genet. 46, 266-271. doi: 10.1136/jmg.2008.063701.
18. Berry-Kravis, E. M., Hessl, D., Rathmell, B., Zarevics, P., Cherubini, M., Walton-Bowen, K., et al. (2012). Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci. Transl. Med. 4:152ra127. doi: 10.1126/scitranslmed.3004214.
19. Berry-Kravis, E., Knox, A., and Hervey, C. (2011). Targeted treatments for fragile X syndrome. J. Neurodev. Disord.3, 193-210. doi: 10.1007/s11689-011-9074-7.
20. Berry-Kravis, E., Krause, S. E., Block, S. S., Guter, S., Wuu, J., Leurgans, S., et al. (2006). Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. J. Child Adolesc. Psychopharmacol. 16, 525-540. doi: 10.1089/cap.2006.16.525.
21. Berry-Kravis, E., Sumis, A., Hervey, C., Nelson, M., Porges, S. W., Weng, N., et al. (2008). Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J. Dev. Behav. Pediatr. 29, 293-302. doi: 10.1097/DBP.0b013e31817dc447.
22. Bhakar, A. L., Dolen, G., and Bear, M. F. (2012). The pathophysiology of fragile, X (and what it teaches us about synapses). Annu. Rev. Neurosci. 35, 417-443. doi: 10.1146/annurev-neuro-060909-153138.
23. Bhattacharya, A., Kaphzan, H., Alvarez-Dieppa, A. C., Murphy, J. P., Pierre, P., and Klann, E. (2012). Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic and behavioral phenotypes in fragile X syndrome mice.Neuron 76, 325-337. doi: 10.1016/j.neuron.2012.07.022.
24. Bienvenu, T., and Chelly, J. (2006). Molecular genetics of Rett syndrome: when DNA methylation goes unrecognized. Nat. Rev. Genet. 7, 415-426. doi: 10.1038/nrg1878.
25. Bilousova, T. V., Dansie, L., Ngo, M., Aye, J., Charles, J. R., Ethell, D. W., et al. (2009). Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J. Med. Genet. 46, 94-102. doi: 10.1136/jmg.2008.061796.
26. Blue, M. E., Kaufmann, W. E., Bressler, J., Eyring, C., O’driscoll, C., Naidu, S., et al. (2011). Temporal and regional alterations in NMDA receptor expression in Mecp2-null mice. Anat. Rec. (Hoboken) 294, 1624-1634. doi: 10.1002/ar.21380.
27. Blue, M. E., Naidu, S., and Johnston, M. V. (1999). Development of amino acid receptors in frontal cortex from girls with Rett syndrome. Ann. Neurol. 45, 541-545. doi: 10.1002/1531-8249(199904)45:4<541::aid-ana21>3.0.co;2-2.
28. Boda, B., Mendez, P., Boury-Jamot, B., Magara, F., and Muller, D. (2014). Reversal of activity-mediated spine dynamics and learning impairment in a mouse model of Fragile X syndrome. Eur. J. Neurosci. 39, 1130-1137. doi: 10.1111/ejn.12488.
29. Borrell-Pagès, M., Canals, J. M., Cordelières, F. P., Parker, J. A., Pineda, J. R., Grange, G., et al. (2006). Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J. Clin. Invest. 116, 1410-1424. doi: 10.1172/jci27607.
30. Bortolotto, Z. A., Fitzjohn, S. M., and Collingridge, G. L. (1999). Roles of metabotropic glutamate receptors in LTP and LTD in the hippocampus. Curr. Opin. Neurobiol. 9, 299-304. doi: 10.1016/s0959-4388(99)80044-0.
31. Braat, S., and Kooy, R. F. (2014). Fragile X syndrome neurobiology translates into rational therapy. Drug Discov. Today 19, 510-519. doi: 10.1016/j.drudis.2014.01.013.
32. Braithwaite, S. P., Paul, S., Nairn, A. C., and Lombroso, P. J. (2006). Synaptic plasticity: one STEP at a time. Trends Neurosci. 29, 452-458. doi: 10.1016/j.tins.2006.06.007.
33. Brendel, C., Belakhov, V., Werner, H., Wegener, E., Gärtner, J., Nudelman, I., et al. (2011). Readthrough of nonsense mutations in Rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model. J. Mol. Med. (Berl.) 89, 389-398. doi: 10.1007/s00109-010-0704-4.
34. Brown, M. R., Kronengold, J., Gazula, V. R., Chen, Y., Strumbos, J. G., Sigworth, F. J., et al. (2010). Fragile X mental retardation protein controls gating of the sodium-activated potassium channel slack. Nat. Neurosci. 13, 819-821. doi: 10.1038/nn.2563.
35. Brücke, T., Sofic, E., Killian, W., Rett, A., and Riederer, P. (1987). Reduced concentrations and increased metabolism of biogenic amines in a single case of Rett-syndrome: a postmortem brain study. J. Neural Transm. 68, 315-324. doi: 10.1007/bf02098506.
36. Burket, J. A., Benson, A. D., Tang, A. H., and Deutsch, S. I. (2014). Rapamycin improves sociability in the BTBR T(+)Itpr3(tf)/J mouse model of autism spectrum disorders. Brain Res. Bull. 100, 70-75. doi: 10.1016/j.brainresbull.2013.11.005.
37. Busquets-Garcia, A., Gomis-González, M., Guegan, T., Agustín-Pavón, C., Pastor, A., Mato, S., et al. (2013). Targeting the endocannabinoid system in the treatment of fragile X syndrome. Nat. Med. 19, 603-607. doi: 10.1038/nm.3127.
38. Çaku, A., Pellerin, D., Bouvier, P., Riou, E., and Corbin, F. (2014). Effect of lovastatin on behavior in children and adults with fragile X syndrome: an open-label study. Am. J. Med. Genet. A 164A, 2834-2842. doi: 10.1002/ajmg.a.36750.
39. Calfa, G., Li, W., Rutherford, J. M., and Pozzo-Miller, L. (2015). Excitation/inhibition imbalance and impaired synaptic inhibition in hippocampal area CA3 of Mecp2 knockout mice. Hippocampus 25, 159-168. doi: 10.1002/hipo.22360.
40. Castrén, E., Elgersma, Y., Maffei, L., and Hagerman, R. (2012). Treatment of neurodevelopmental disorders in adulthood. J. Neurosci. 32, 14074-14079. doi: 10.1523/JNEUROSCI.3287-12.2012.
41. Castro, J., Garcia, R. I., Kwok, S., Banerjee, A., Petravicz, J., Woodson, J., et al. (2014). Functional recovery with recombinant human IGF1 treatment in a mouse model of Rett syndrome. Proc. Natl. Acad. Sci. U S A 111, 9941-9946. doi: 10.1073/pnas.1311685111.
42. Castro, J., Mellios, N., and Sur, M. (2013). Mechanisms and therapeutic challenges in autism spectrum disorders: insights from Rett syndrome. Curr. Opin. Neurol. 26, 154-159. doi: 10.1097/WCO.0b013e32835f19a7.
43. Cerovic, M., d’Isa, R., Tonini, R., and Brambilla, R. (2013). Molecular and cellular mechanisms of dopamine-mediated behavioral plasticity in the striatum. Neurobiol. Learn. Mem. 105, 63-80. doi: 10.1016/j.nlm.2013.06.013.
44. Chahrour, M., and Zoghbi, H. Y. (2007). The story of Rett syndrome: from clinic to neurobiology. Neuron 56, 422-437. doi: 10.1016/j.neuron.2007.10.001.
45. Chang, S., Bray, S. M., Li, Z., Zarnescu, D. C., He, C., Jin, P., et al. (2008). Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila. Nat. Chem. Biol. 4, 256-263. doi: 10.1038/nchembio.78.
46. Chang, Q., Khare, G., Dani, V., Nelson, S., and Jaenisch, R. (2006). The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. Neuron 49, 341-348. doi: 10.1016/j.neuron.2005.12.027.
47. Chao, H. T., Chen, H., Samaco, R. C., Xue, M., Chahrour, M., Yoo, J., et al. (2010). Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. Nature 468, 263-269. doi: 10.1038/nature09582.
48. Chapleau, C. A., Lane, J., Larimore, J., Li, W., Pozzo-Miller, L., and Percy, A. K. (2013b). Recent progress in Rett syndrome and MeCP2 Dysfunction: assessment of potential treatment options. Future Neurol. 8, 21-28. doi: 10.2217/fnl.12.79.
49. Chapleau, C. A., Lane, J., Pozzo-Miller, L., and Percy, A. K. (2013a). Evaluation of current pharmacological treatment options in the management of Rett syndrome: from the present to future therapeutic alternatives. Curr. Clin. Pharmacol. 8, 358-369. doi: 10.2174/15748847113086660069.
50. Chapleau, C. A., Larimore, J. L., Theibert, A., and Pozzo-Miller, L. (2009). Modulation of dendritic spine development and plasticity by BDNF and vesicular trafficking: fundamental roles in neurodevelopmental disorders associated with mental retardation and autism. J. Neurodev. Disord. 1, 185-196. doi: 10.1007/s11689-009-9027-6.
51. Chen, R. Z., Akbarian, S., Tudor, M., and Jaenisch, R. (2001). Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat. Genet. 27, 327-331. doi: 10.1038/85906.
52. Chen, W. G., Chang, Q., Lin, Y., Meissner, A., West, A. E., Griffith, E. C., et al. (2003). Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science 302, 885-889. doi: 10.1126/science.1086446.
53. Chen, L. Y., Rex, C. S., Babayan, A. H., Kramár, E. A., Lynch, G., Gall, C. M., et al. (2010). Physiological activation of synaptic Rac>PAK (p-21 activated kinase) signaling is defective in a mouse model of fragile X syndrome. J. Neurosci. 30, 10977-10984. doi: 10.1523/JNEUROSCI.1077-10.2010.
54. Cheng, C., Sourial, M., and Doering, L. C. (2012). Astrocytes and developmental plasticity in fragile X. Neural Plast.2012:197491. doi: 10.1155/2012/197491.
55. Chevaleyre, V., Takahashi, K. A., and Castillo, P. E. (2006). Endocannabinoid-mediated synaptic plasticity in the CNS. Annu. Rev. Neurosci. 29, 37-76. doi: 10.1146/annurev.neuro.29.051605.112834.
56. Chez, M. G., Burton, Q., Dowling, T., Chang, M., Khanna, P., and Kramer, C. (2007). Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. J. Child Neurol. 22, 574-579. doi: 10.1177/0883073807302611.
57. Chiu, C. T., and Chuang, D. M. (2010). Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Pharmacol. Ther. 128, 281-304. doi: 10.1016/j.pharmthera.2010.07.006.
58. Chugani, D. C. (2002). Role of altered brain serotonin mechanisms in autism. Mol. Psychiatry 7(Suppl. 2), S16-S17. doi: 10.1038/sj.mp.4001167.
59. Cobb, S., Guy, J., and Bird, A. (2010). Reversibility of functional deficits in experimental models of Rett syndrome.Biochem. Soc. Trans. 38, 498-506. doi: 10.1042/BST0380498.
60. Cohen, S., Gabel, H. W., Hemberg, M., Hutchinson, A. N., Sadacca, L. A., Ebert, D. H., et al. (2011). Genome-wide activity-dependent MeCP2 phosphorylation regulates nervous system development and function. Neuron 72, 72-85. doi: 10.1016/j.neuron.2011.08.022.
61. Cohen, P., and Goedert, M. (2004). GSK3 inhibitors: development and therapeutic potential. Nat. Rev. Drug Discov.3, 479-487. doi: 10.1038/nrd1415.
62. Connelly, J. F. (1993). Vigabatrin. Ann. Pharmacother. 27, 197-204..
63. Corvin, A. P., Molinos, I., Little, G., Donohoe, G., Gill, M., Morris, D. W., et al. (2012). Insulin-like growth factor 1 (IGF1) and its active peptide (1-3)IGF1 enhance the expression of synaptic markers in neuronal circuits through different cellular mechanisms. Neurosci. Lett. 520, 51-56. doi: 10.1016/j.neulet.2012.05.029.
64. Costa, L., Spatuzza, M., D’Antoni, S., Bonaccorso, C. M., Trovato, C., Musumeci, S. A., et al. (2012). Activation of 5-HT7 serotonin receptors reverses metabotropic glutamate receptor-mediated synaptic plasticity in wild-type and Fmr1 knockout mice, a model of Fragile X syndrome. Biol. Psychiatry 72, 924-933. doi: 10.1016/j.biopsych.2012.06.008.
65. Cuesto, G., Enriquez-Barreto, L., Caramés, C., Cantarero, M., Gasull, X., Sandi, C., et al. (2011). Phosphoinositide-3-kinase activation controls synaptogenesis and spinogenesis in hippocampal neurons. J. Neurosci. 31, 2721-2733. doi: 10.1523/JNEUROSCI.4477-10.2011.
66. Curia, G., Gualtieri, F., Bartolomeo, R., Vezzali, R., and Biagini, G. (2013). Resilience to audiogenic seizures is associated with p-ERK1/2 dephosphorylation in the subiculum of Fmr1 knockout mice. Front. Cell. Neurosci. 7:46. doi: 10.3389/fncel.2013.00046.
67. Dansie, L. E., Phommahaxay, K., Okusanya, A. G., Uwadia, J., Huang, M., Rotschafer, S. E., et al. (2013). Long-lasting effects of minocycline on behavior in young but not adult Fragile X mice. Neuroscience 246, 186-198. doi: 10.1016/j.neuroscience.2013.04.058.
68. Darnell, J. C., and Klann, E. (2013). The translation of translational control by FMRP: therapeutic targets for FXS.Nat. Neurosci. 16, 1530-1536. doi: 10.1038/nn.3379.
69. De Felice, C., Signorini, C., Leoncini, S., Pecorelli, A., Durand, T., Valacchi, G., et al. (2012). The role of oxidative stress in Rett syndrome: an overview. Ann. N Y Acad. Sci. 1259, 121-135. doi: 10.1111/j.1749-6632.2012.06611.x.
70. Delorme, R., Ey, E., Toro, R., Leboyer, M., Gillberg, C., and Bourgeron, T. (2013). Progress toward treatments for synaptic defects in autism. Nat. Med. 19, 685-694. doi: 10.1038/nm.3193.
71. Deng, P. Y., Rotman, Z., Blundon, J. A., Cho, Y., Cui, J., Cavalli, V., et al. (2013). FMRP regulates neurotransmitter release and synaptic information transmission by modulating action potential duration via BK channels. Neuron77, 696-711. doi: 10.1016/j.neuron.2012.12.018.
72. Deogracias, R., Yazdani, M., Dekkers, M. P., Guy, J., Ionescu, M. C., Vogt, K. E., et al. (2012). Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome. Proc. Natl. Acad. Sci. U S A 109, 14230-14235. doi: 10.1073/pnas.1206093109.
73. Derecki, N. C., Cronk, J. C., and Kipnis, J. (2013). The role of microglia in brain maintenance: implications for Rett syndrome. Trends Immunol. 34, 144-150. doi: 10.1016/j.it.2012.10.002.
74. Devlin, B., Cook, E. H. Jr., Coon, H., Dawson, G., Grigorenko, E. L., McMahon, W., et al. (2005). Autism and the serotonin transporter: the long and short of it. Mol. Psychiatry 10, 1110-1116. doi: 10.1038/sj.mp.4001724.
75. de Vrij, F. M., Levenga, J., van der Linde, H. C., Koekkoek, S. K., De Zeeuw, C. I., Nelson, D. L., et al. (2008). Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol. Dis. 31, 127-132. doi: 10.1016/j.nbd.2008.04.002.
76. D’Hulst, C., De Geest, N., Reeve, S. P., Van Dam, D., De Deyn, P. P., Hassan, B. A., et al. (2006). Decreased expression of the GABAA receptor in fragile X syndrome. Brain Res. 1121, 238-245. doi: 10.1016/j.brainres.2006.08.115.
77. D’Hulst, C., Heulens, I., Brouwer, J. R., Willemsen, R., De Geest, N., Reeve, S. P., et al. (2009). Expression of the GABAergic system in animal models for fragile X syndrome and fragile X associated tremor/ataxia syndrome (FXTAS). Brain Res. 1253, 176-183. doi: 10.1016/j.brainres.2008.11.075.
78. Dolan, B. M., Duron, S. G., Campbell, D. A., Vollrath, B., Shankaranarayana Rao, B. S., Ko, H. Y., et al. (2013). Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486. Proc. Natl. Acad. Sci. U S A 110, 5671-5676. doi: 10.1073/pnas.1219383110.
79. Dölen, G., and Bear, M. F. (2008). Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome. J. Physiol. 586, 1503-1508. doi: 10.1113/jphysiol.2008.150722.
80. Doll, C. A., and Broadie, K. (2014). Impaired activity-dependent neural circuit assembly and refinement in autism spectrum disorder genetic models. Front. Cell. Neurosci. 8:30. doi: 10.3389/fncel.2014.00030.
81. Domes, G., Heinrichs, M., Kumbier, E., Grossmann, A., Hauenstein, K., and Herpertz, S. C. (2013). Effects of intranasal oxytocin on the neural basis of face processing in autism spectrum disorder. Biol. Psychiatry 74, 164-171. doi: 10.1016/j.biopsych.2013.02.007.
82. Durand, S., Patrizi, A., Quast, K. B., Hachigian, L., Pavlyuk, R., Saxena, A., et al. (2012). NMDA receptor regulation prevents regression of visual cortical function in the absence of Mecp2. Neuron 76, 1078-1090. doi: 10.1016/j.neuron.2012.12.004.
83. Dziembowska, M., Pretto, D. I., Janusz, A., Kaczmarek, L., Leigh, M. J., Gabriel, N., et al. (2013). High MMP-9 activity levels in fragile X syndrome are lowered by minocycline. Am. J. Med. Genet. A 161A, 1897-1903. doi: 10.1002/ajmg.a.36023.
84. Eadie, B. D., Cushman, J., Kannangara, T. S., Fanselow, M. S., and Christie, B. R. (2012). NMDA receptor hypofunction in the dentate gyrus and impaired context discrimination in adult Fmr1 knockout mice.Hippocampus 22, 241-254. doi: 10.1002/hipo.20890.
85. Ebert, D. H., and Greenberg, M. E. (2013). Activity-dependent neuronal signalling and autism spectrum disorder.Nature 493, 327-337. doi: 10.1038/nature11860.
86. Erickson, C. A., and Chambers, J. E. (2006). Memantine for disruptive behavior in autistic disorder. J. Clin. Psychiatry 67:1000. doi: 10.4088/jcp.v67n0619h.
87. Erickson, C. A., Mullett, J. E., and McDougle, C. J. (2009). Open-label memantine in fragile X syndrome. J. Autism Dev. Disord. 39, 1629-1635. doi: 10.1007/s10803-009-0807-3.
88. Erickson, C. A., Mullett, J. E., and McDougle, C. J. (2010). Brief report: acamprosate in fragile X syndrome. J. Autism Dev. Disord. 40, 1412-1416. doi: 10.1007/s10803-010-0988-9.
89. Erickson, C. A., Wink, L. K., Ray, B., Early, M. C., Stiegelmeyer, E., Mathieu-Frasier, L., et al. (2013). Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. Psychopharmacology (Berl) 228, 75-84. doi: 10.1007/s00213-013-3022-z.
90. Ethell, I. M., and Ethell, D. W. (2007). Matrix metalloproteinases in brain development and remodeling: synaptic functions and targets. J. Neurosci. Res. 85, 2813-2823. doi: 10.1002/jnr.21273.
91. Franklin, A. V., King, M. K., Palomo, V., Martinez, A., McMahon, L. L., and Jope, R. S. (2014). Glycogen synthase kinase-3 inhibitors reverse deficits in long-term potentiation and cognition in fragile X mice. Biol. Psychiatry 75, 198-206. doi: 10.1016/j.biopsych.2013.08.003.
92. Fulks, J. L., O’Bryhim, B. E., Wenzel, S. K., Fowler, S. C., Vorontsova, E., Pinkston, J. W., et al. (2010). Dopamine release and uptake impairments and behavioral alterations observed in mice that model fragile X mental retardation syndrome. ACS Chem. Neurosci. 1, 679-690. doi: 10.1021/cn100032f.
93. Gadalla, K. K., Bailey, M. E., and Cobb, S. R. (2011). MeCP2 and Rett syndrome: reversibility and potential avenues for therapy. Biochem. J. 439, 1-14. doi: 10.1042/bj20110648.
94. Gandhi, R. M., Kogan, C. S., and Messier, C. (2014). 2-Methyl-6-(phenylethynyl) pyridine (MPEP) reverses maze learning and PSD-95 deficits in Fmr1 knock-out mice. Front. Cell. Neurosci. 8:70. doi: 10.3389/fncel.2014.00070.
95. Gantois, I., Pop, A. S., de Esch, C. E., Buijsen, R. A., Pooters, T., Gomez-Mancilla, B., et al. (2013). Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice. Behav. Brain Res. 239, 72-79. doi: 10.1016/j.bbr.2012.10.059.
96. Garber, K. B., Visootsak, J., and Warren, S. T. (2008). Fragile X syndrome. Eur. J. Hum. Genet. 16, 666-672. doi: 10.1038/ejhg.2008.61.
97. Gassmann, M., and Bettler, B. (2012). Regulation of neuronal GABA(B) receptor functions by subunit composition.Nat. Rev. Neurosci. 13, 380-394. doi: 10.1038/nrn3249.
98. Gellynck, E., Heyninck, K., Andressen, K. W., Haegeman, G., Levy, F. O., Vanhoenacker, P., et al. (2013). The serotonin 5-HT7 receptors: two decades of research. Exp. Brain Res. 230, 555-568. doi: 10.1007/s00221-013-3694-y.
99. Girard, M., Couvert, P., Carrié, A., Tardieu, M., Chelly, J., Beldjord, C., et al. (2001). Parental origin of de novo MECP2 mutations in Rett syndrome. Eur. J. Hum. Genet. 9, 231-236. doi: 10.1038/sj.ejhg.5200618.
100. Gkogkas, C. G., Khoutorsky, A., Ran, I., Rampakakis, E., Nevarko, T., Weatherill, D. B., et al. (2013). Autism-related deficits via dysregulated eIF4E-dependent translational control. Nature 493, 371-377. doi: 10.1038/nature11628.
101. Glaze, D. G., Percy, A. K., Skinner, S., Motil, K. J., Neul, J. L., Barrish, J. O., et al. (2010). Epilepsy and the natural history of Rett syndrome. Neurology 74, 909-912. doi: 10.1212/wnl.0b013e3181d6b852.
102. Gocel, J., and Larson, J. (2012). Synaptic NMDA receptor-mediated currents in anterior piriform cortex are reduced in the adult fragile X mouse. Neuroscience 221, 170-181. doi: 10.1016/j.neuroscience.2012.06.052.
103. Goebel-Goody, S. M., Baum, M., Paspalas, C. D., Fernandez, S. M., Carty, N. C., Kurup, P., et al. (2012b). Therapeutic implications for striatal-enriched protein tyrosine phosphatase (STEP) in neuropsychiatric disorders. Pharmacol. Rev. 64, 65-87. doi: 10.1124/pr.110.003053.
104. Goebel-Goody, S. M., and Lombroso, P. J. (2012). Taking STEPs forward to understand fragile X syndrome. Results Probl. Cell Differ. 54, 223-241. doi: 10.1007/978-3-642-21649-7_12.
105. Goebel-Goody, S. M., Wilson-Wallis, E. D., Royston, S., Tagliatela, S. M., Naegele, J. R., and Lombroso, P. J. (2012a). Genetic manipulation of STEP reverses behavioral abnormalities in a fragile X syndrome mouse model. Genes Brain Behav. 11, 586-600. doi: 10.1111/j.1601-183x.2012.00781.x.
106. Gordon, I., Vander Wyk, B. C., Bennett, R. H., Cordeaux, C., Lucas, M. V., Eilbott, J. A., et al. (2013). Oxytocin enhances brain function in children with autism. Proc. Natl. Acad. Sci. U S A 110, 20953-20958. doi: 10.1073/pnas.1312857110.
107. Gralle, M., and Ferreira, S. T. (2007). Structure and functions of the human amyloid precursor protein: the whole is more than the sum of its parts. Prog. Neurobiol. 82, 11-32. doi: 10.1016/j.pneurobio.2007.02.001.
108. Gross, C., and Bassell, G. J. (2012). Excess protein synthesis in FXS patient lymphoblastoid cells can be rescued with a p110beta-selective inhibitor. Mol. Med. 18, 336-345. doi: 10.2119/molmed.2011.00363.
109. Gross, C., and Bassell, G. J. (2014). Neuron-specific regulation of class I PI3K catalytic subunits and their dysfunction in brain disorders. Front. Mol. Neurosci. 7:12. doi: 10.3389/fnmol.2014.00012.
110. Gross, C., Berry-Kravis, E. M., and Bassell, G. J. (2012). Therapeutic strategies in fragile X syndrome: dysregulated mGluR signaling and beyond. Neuropsychopharmacology 37, 178-195. doi: 10.1038/npp.2011.137.
111. Gross, C., Nakamoto, M., Yao, X., Chan, C. B., Yim, S. Y., Ye, K., et al. (2010). Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome. J. Neurosci. 30, 10624-10638. doi: 10.1523/jneurosci.0402-10.2010.
112. Gross, C., Yao, X., Pong, D. L., Jeromin, A., and Bassell, G. J. (2011). Fragile X mental retardation protein regulates protein expression and mRNA translation of the potassium channel Kv4.2. J. Neurosci. 31, 5693-5698. doi: 10.1523/jneurosci.6661-10.2011.
113. Guo, W., Murthy, A. C., Zhang, L., Johnson, E. B., Schaller, E. G., Allan, A. M., et al. (2012). Inhibition of GSK3beta improves hippocampus-dependent learning and rescues neurogenesis in a mouse model of fragile X syndrome.Hum. Mol. Genet. 21, 681-691. doi: 10.1093/hmg/ddr501.
114. Guy, J., Cheval, H., Selfridge, J., and Bird, A. (2011). The role of MeCP2 in the brain. Annu. Rev. Cell Dev. Biol. 27, 631-652. doi: 10.1146/annurev-cellbio-092910-154121.
115. Guy, J., Gan, J., Selfridge, J., Cobb, S., and Bird, A. (2007). Reversal of neurological defects in a mouse model of Rett syndrome. Science 315, 1143-1147. doi: 10.1126/science.1138389.
116. Guy, J., Hendrich, B., Holmes, M., Martin, J. E., and Bird, A. (2001). A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat. Genet. 27, 322-326. doi: 10.1038/85899.
117. Hagberg, B., Aicardi, J., Dias, K., and Ramos, O. (1983). A progressive syndrome of autism, dementia, ataxia and loss of purposeful hand use in girls: Rett’s syndrome: report of 35 cases. Ann. Neurol. 14, 471-479. doi: 10.1002/ana.410140412.
118. Hagerman, R. J., Des-Portes, V., Gasparini, F., Jacquemont, S., and Gomez-Mancilla, B. (2014). Translating molecular advances in fragile X syndrome into therapy: a review. J. Clin. Psychiatry 75, e294-e307. doi: 10.4088/jcp.13r08714.
119. Hagerman, R. J., Hills, J., Scharfenaker, S., and Lewis, H. (1999). Fragile X syndrome and selective mutism. Am. J. Med. Genet. 83, 313-317. doi: 10.1002/(sici)1096-8628(19990402)83:4<313::aid-ajmg15>3.0.co;2-f.
120. Hagerman, R. J., and Polussa, J. (2015). Treatment of the psychiatric problems associated with fragile X syndrome.Curr. Opin. Psychiatry 28, 107-112. doi: 10.1097/yco.0000000000000131.
121. Hall, S. S., Lightbody, A. A., McCarthy, B. E., Parker, K. J., and Reiss, A. L. (2012). Effects of intranasal oxytocin on social anxiety in males with fragile X syndrome. Psychoneuroendocrinology 37, 509-518. doi: 10.1016/j.psyneuen.2011.07.020.
122. Harrington, R. A., Lee, L. C., Crum, R. M., Zimmerman, A. W., and Hertz-Picciotto, I. (2013). Serotonin hypothesis of autism: implications for selective serotonin reuptake inhibitor use during pregnancy. Autism Res. 6, 149-168. doi: 10.1002/aur.1288.
123. Hay, N., and Sonenberg, N. (2004). Upstream and downstream of mTOR. Genes Dev. 18, 1926-1945. doi: 10.1101/gad.1212704.
124. Hayashi, M. L., Choi, S. Y., Rao, B. S., Jung, H. Y., Lee, H. K., Zhang, D., et al. (2004). Altered cortical synaptic morphology and impaired memory consolidation in forebrain-specific dominant-negative PAK transgenic mice.Neuron 42, 773-787. doi: 10.1016/j.neuron.2004.05.003.
125. Hayashi, M. L., Rao, B. S., Seo, J. S., Choi, H. S., Dolan, B. M., Choi, S. Y., et al. (2007). Inhibition of p21-activated kinase rescues symptoms of fragile X syndrome in mice. Proc. Natl. Acad. Sci. U S A 104, 11489-11494. doi: 10.1073/pnas.0705003104.
126. Hays, S. A., Huber, K. M., and Gibson, J. R. (2011). Altered neocortical rhythmic activity states in Fmr1 KO mice are due to enhanced mGluR5 signaling and involve changes in excitatory circuitry. J. Neurosci. 31, 14223-14234. doi: 10.1523/jneurosci.3157-11.2011.
127. He, Q., Nomura, T., Xu, J., and Contractor, A. (2014). The developmental switch in GABA polarity is delayed in fragile X mice. J. Neurosci. 34, 446-450. doi: 10.1523/jneurosci.4447-13.2014.
128. Hebert, B., Pietropaolo, S., Meme, S., Laudier, B., Laugeray, A., Doisne, N., et al. (2014). Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by a BKCa channel opener molecule. Orphanet J. Rare Dis. 9:124. doi: 10.1186/s13023-014-0124-6.
129. Heifets, B. D., and Castillo, P. E. (2009). Endocannabinoid signaling and long-term synaptic plasticity. Annu. Rev. Physiol. 71, 283-306. doi: 10.1146/annurev.physiol.010908.163149.
130. Henderson, C., Wijetunge, L., Kinoshita, M. N., Shumway, M., Hammond, R. S., Postma, F. R., et al. (2012). Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci. Transl. Med. 4:152ra128. doi: 10.1126/scitranslmed.3004218.
131. Hessl, D., Nguyen, D. V., Green, C., Chavez, A., Tassone, F., Hagerman, R. J., et al. (2009). A solution to limitations of cognitive testing in children with intellectual disabilities: the case of fragile X syndrome. J. Neurodev. Disord. 1, 33-45. doi: 10.1007/s11689-008-9001-8.
132. Heulens, I., D’Hulst, C., Van Dam, D., De Deyn, P. P., and Kooy, R. F. (2012). Pharmacological treatment of fragile X syndrome with GABAergic drugs in a knockout mouse model. Behav. Brain Res. 229, 244-249. doi: 10.1016/j.bbr.2012.01.031.
133. Hoeffer, C. A., and Klann, E. (2010). mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci. 33, 67-75. doi: 10.1016/j.tins.2009.11.003.
134. Hoeffer, C. A., Sanchez, E., Hagerman, R. J., Mu, Y., Nguyen, D. V., Wong, H., et al. (2012). Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome. Genes Brain Behav. 11, 332-341. doi: 10.1111/j.1601-183x.2012.00768.x.
135. Hollander, E., Phillips, A., Chaplin, W., Zagursky, K., Novotny, S., Wasserman, S., et al. (2005). A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism.Neuropsychopharmacology 30, 582-589. doi: 10.1038/sj.npp.1300627.
136. Hollander, E., Soorya, L., Chaplin, W., Anagnostou, E., Taylor, B. P., Ferretti, C. J., et al. (2012). A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. Am. J. Psychiatry 169, 292-299. doi: 10.1176/appi.ajp.2011.10050764.
137. Horwood, J. M., Dufour, F., Laroche, S., and Davis, S. (2006). Signalling mechanisms mediated by the phosphoinositide 3-kinase/Akt cascade in synaptic plasticity and memory in the rat. Eur. J. Neurosci. 23, 3375-3384. doi: 10.1111/j.1460-9568.2006.04859.x.
138. Hu, H., Qin, Y., Bochorishvili, G., Zhu, Y., van Aelst, L., and Zhu, J. J. (2008). Ras signaling mechanisms underlying impaired GluR1-dependent plasticity associated with fragile X syndrome. J. Neurosci. 28, 7847-7862. doi: 10.1523/jneurosci.1496-08.2008.
139. Huguet, G., Ey, E., and Bourgeron, T. (2013). The genetic landscapes of autism spectrum disorders. Annu. Rev. Genomics Hum. Genet. 14, 191-213. doi: 10.1146/annurev-genom-091212-153431.
140. Huntley, G. W. (2012). Synaptic circuit remodelling by matrix metalloproteinases in health and disease. Nat. Rev. Neurosci. 13, 743-757. doi: 10.1038/nrn3320.
141. Imbesi, M., Uz, T., Manev, R., Sharma, R. P., and Manev, H. (2008). Minocycline increases phosphorylation and membrane insertion of neuronal GluR1 receptors. Neurosci. Lett. 447, 134-137. doi: 10.1016/j.neulet.2008.10.006.
142. Jacquemont, S., Berry-Kravis, E., Hagerman, R., von Raison, F., Gasparini, F., Apostol, G., et al. (2014). The challenges of clinical trials in fragile X syndrome. Psychopharmacology (Berl) 231, 1237-1250. doi: 10.1007/s00213-013-3289-0.
143. Jacquemont, S., Curie, A., des Portes, V., Torrioli, M. G., Berry-Kravis, E., Hagerman, R. J., et al. (2011). Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci. Transl. Med. 3:64ra61. doi: 10.1126/scitranslmed.3001708.
144. Janusz, A., Milek, J., Perycz, M., Pacini, L., Bagni, C., Kaczmarek, L., et al. (2013). The fragile X mental retardation protein regulates matrix metalloproteinase 9 mRNA at synapses. J. Neurosci. 33, 18234-18241. doi: 10.1523/JNEUROSCI.2207-13.2013.
145. Jay, T. M. (2003). Dopamine: a potential substrate for synaptic plasticity and memory mechanisms. Prog. Neurobiol. 69, 375-390. doi: 10.1016/s0301-0082(03)00085-6.
146. Jope, R. S., and Roh, M. S. (2006). Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr. Drug Targets 7, 1421-1434. doi: 10.2174/1389450110607011421.
147. Jung, B. P., Jugloff, D. G., Zhang, G., Logan, R., Brown, S., and Eubanks, J. H. (2003). The expression of methyl CpG binding factor MeCP2 correlates with cellular differentiation in the developing rat brain and in cultured cells. J. Neurobiol. 55, 86-96. doi: 10.1002/neu.10201.
148. Jung, K. M., Sepers, M., Henstridge, C. M., Lassalle, O., Neuhofer, D., Martin, H., et al. (2012). Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. Nat. Commun. 3:1080. doi: 10.1038/ncomms2045.
149. Katz, D. M. (2014). Brain-derived neurotrophic factor and Rett syndrome. Handb. Exp. Pharmacol. 220, 481-495. doi: 10.1007/978-3-642-45106-5_18.
150. Katz, D. M., Berger-Sweeney, J. E., Eubanks, J. H., Justice, M. J., Neul, J. L., Pozzo-Miller, L., et al. (2012). Preclinical research in Rett syndrome: setting the foundation for translational success. Dis. Model. Mech. 5, 733-745. doi: 10.1242/dmm.011007.
151. Kelleher, R. J. 3rd, Govindarajan, A., Jung, H. Y., Kang, H., and Tonegawa, S. (2004). Translational control by MAPK signaling in long-term synaptic plasticity and memory. Cell 116, 467-479. doi: 10.1016/s0092-8674(04)00115-1.
152. Khwaja, O. S., Ho, E., Barnes, K. V., O’Leary, H. M., Pereira, L. M., Finkelstein, Y., et al. (2014). Safety, pharmacokinetics and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome. Proc. Natl. Acad. Sci. U S A 111, 4596-4601. doi: 10.1073/pnas.1311141111.
153. Kim, G. E., and Kaczmarek, L. K. (2014). Emerging role of the KCNT1 Slack channel in intellectual disability. Front. Cell. Neurosci. 8:209. doi: 10.3389/fncel.2014.00209.
154. Kim, S. H., Markham, J. A., Weiler, I. J., and Greenough, W. T. (2008). Aberrant early-phase ERK inactivation impedes neuronal function in fragile X syndrome. Proc. Natl. Acad. Sci. U S A 105, 4429-4434. doi: 10.1073/pnas.0800257105.
155. King, M. K., and Jope, R. S. (2013). Lithium treatment alleviates impaired cognition in a mouse model of fragile X syndrome. Genes Brain Behav. 12, 723-731. doi: 10.1111/gbb.12071.
156. Klose, R. J., and Bird, A. P. (2006). Genomic DNA methylation: the mark and its mediators. Trends Biochem. Sci.31, 89-97. doi: 10.1016/j.tibs.2005.12.008.
157. Knobloch, H. S., and Grinevich, V. (2014). Evolution of oxytocin pathways in the brain of vertebrates. Front. Behav. Neurosci. 8:31. doi: 10.3389/fnbeh.2014.00031.
158. Kolevzon, A., Mathewson, K. A., and Hollander, E. (2006). Selective serotonin reuptake inhibitors in autism: a review of efficacy and tolerability. J. Clin. Psychiatry 67, 407-414. doi: 10.4088/jcp.v67n0311.
159. Kreis, P., and Barnier, J. V. (2009). PAK signalling in neuronal physiology. Cell. Signal. 21, 384-393. doi: 10.1016/j.cellsig.2008.11.001.
160. Kron, M., Howell, C. J., Adams, I. T., Ransbottom, M., Christian, D., Ogier, M., et al. (2012). Brain activity mapping in Mecp2 mutant mice reveals functional deficits in forebrain circuits, including key nodes in the default mode network, that are reversed with ketamine treatment. J. Neurosci. 32, 13860-13872. doi: 10.1523/JNEUROSCI.2159-12.2012.
161. Kron, M., Lang, M., Adams, I. T., Sceniak, M., Longo, F., and Katz, D. M. (2014). A BDNF loop-domain mimetic acutely reverses spontaneous apneas and respiratory abnormalities during behavioral arousal in a mouse model of Rett syndrome. Dis. Model. Mech. 7, 1047-1055. doi: 10.1242/dmm.016030.
162. Krueger, D. D., Osterweil, E. K., Chen, S. P., Tye, L. D., and Bear, M. F. (2011). Cognitive dysfunction and prefrontal synaptic abnormalities in a mouse model of fragile X syndrome. Proc. Natl. Acad. Sci. U S A 108, 2587-2592. doi: 10.1073/pnas.1013855108.
163. Krumm, N., O’Roak, B. J., Shendure, J., and Eichler, E. E. (2014). A de novo convergence of autism genetics and molecular neuroscience. Trends Neurosci. 37, 95-105. doi: 10.1016/j.tins.2013.11.005.
164. Kumari, R., Castillo, C., and Francesconi, A. (2013). Agonist-dependent signaling by group I metabotropic glutamate receptors is regulated by association with lipid domains. J. Biol. Chem. 288, 32004-32019. doi: 10.1074/jbc.M113.475863.
165. Lai, M. C., Lombardo, M. V., and Baron-Cohen, S. (2014). Autism. Lancet 383, 896-910. doi: 10.1016/S0140-6736(13)61539-1.
166. Landis, S. C., Amara, S. G., Asadullah, K., Austin, C. P., Blumenstein, R., Bradley, E. W., et al. (2012). A call for transparent reporting to optimize the predictive value of preclinical research. Nature 490, 187-191. doi: 10.1038/nature11556.
167. LaSalle, J. M., Goldstine, J., Balmer, D., and Greco, C. M. (2001). Quantitative localization of heterogeneous methyl-CpG-binding protein 2 (MeCP2) expression phenotypes in normal and Rett syndrome brain by laser scanning cytometry. Hum. Mol. Genet. 10, 1729-1740. doi: 10.1093/hmg/10.17.1729.
168. Laurvick, C. L., de Klerk, N., Bower, C., Christodoulou, J., Ravine, D., Ellaway, C., et al. (2006). Rett syndrome in Australia: a review of the epidemiology. J. Pediatr. 148, 347-352. doi: 10.1016/j.jpeds.2005.10.037.
169. Lauterborn, J. C., Truong, G. S., Baudry, M., Bi, X., Lynch, G., and Gall, C. M. (2003). Chronic elevation of brain-derived neurotrophic factor by ampakines. J. Pharmacol. Exp. Ther. 307, 297-305. doi: 10.1124/jpet.103.053694.
170. Lee, H. Y., Ge, W. P., Huang, W., He, Y., Wang, G. X., Rowson-Baldwin, A., et al. (2011). Bidirectional regulation of dendritic voltage-gated potassium channels by the fragile X mental retardation protein. Neuron 72, 630-642. doi: 10.1016/j.neuron.2011.09.033..
171. Lee, H. Y., and Jan, L. Y. (2012). Fragile X syndrome: mechanistic insights and therapeutic avenues regarding the role of potassium channels. Curr. Opin. Neurobiol. 22, 887-894. doi: 10.1016/j.conb.2012.03.010.
172. Leigh, M. J., Nguyen, D. V., Mu, Y., Winarni, T. I., Schneider, A., Chechi, T., et al. (2013). A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome. J. Dev. Behav. Pediatr. 34, 147-155. doi: 10.1097/DBP.0b013e318287cd17.
173. Lekman, A., Witt-Engerstrom, I., Gottfries, J., Hagberg, B. A., Percy, A. K., and Svennerholm, L. (1989). Rett syndrome: biogenic amines and metabolites in postmortem brain. Pediatr. Neurol. 5, 357-362. doi: 10.1016/0887-8994(89)90049-0.
174. Lesch, K. P., and Waider, J. (2012). Serotonin in the modulation of neural plasticity and networks: implications for neurodevelopmental disorders. Neuron 76, 175-191. doi: 10.1016/j.neuron.2012.09.013.
175. Levenga, J., Hayashi, S., de Vrij, F. M., Koekkoek, S. K., van der Linde, H. C., Nieuwenhuizen, I., et al. (2011). AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome. Neurobiol. Dis. 42, 311-317. doi: 10.1016/j.nbd.2011.01.022.
176. Li, W., and Pozzo-Miller, L. (2014). BDNF deregulation in Rett syndrome. Neuropharmacology 76(Pt. C), 737-746. doi: 10.1016/j.neuropharm.2013.03.024.
177. Lim, C. S., Hoang, E. T., Viar, K. E., Stornetta, R. L., Scott, M. M., and Zhu, J. J. (2014). Pharmacological rescue of Ras signaling, GluA1-dependent synaptic plasticity and learning deficits in a fragile X model. Genes Dev. 28, 273-289. doi: 10.1101/gad.232470.113.
178. Lipton, J., and Sahin, M. (2013). Fragile X syndrome therapeutics: translation, meet translational medicine. Neuron77, 212-213. doi: 10.1016/j.neuron.2013.01.009.
179. Maccarrone, M., Rossi, S., Bari, M., De Chiara, V., Rapino, C., Musella, A., et al. (2010). Abnormal mGlu 5 receptor/endocannabinoid coupling in mice lacking FMRP and BC1 RNA. Neuropsychopharmacology 35, 1500-1509. doi: 10.1038/npp.2010.19.
180. Maliszewska-Cyna, E., Bawa, D., and Eubanks, J. H. (2010). Diminished prevalence but preserved synaptic distribution of N-methyl-D-aspartate receptor subunits in the methyl CpG binding protein 2(MeCP2)-null mouse brain. Neuroscience 168, 624-632. doi: 10.1016/j.neuroscience.2010.03.065.
181. Malter, J. S., Ray, B. C., Westmark, P. R., and Westmark, C. J. (2010). Fragile X syndrome and Alzheimer’s disease: another story about APP and beta-amyloid. Curr. Alzheimer Res. 7, 200-206. doi: 10.2174/156720510791050957.
182. Marchetto, M. C., Carromeu, C., Acab, A., Yu, D., Yeo, G. W., Mu, Y., et al. (2010). A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 143, 527-539. doi: 10.1016/j.cell.2010.10.016.
183. Martinowich, K., Hattori, D., Wu, H., Fouse, S., He, F., Hu, Y., et al. (2003). DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. Science 302, 890-893. doi: 10.1126/science.1090842.
184. Massa, S. M., Yang, T., Xie, Y., Shi, J., Bilgen, M., Joyce, J. N., et al. (2010). Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. J. Clin. Invest. 120, 1774-1785. doi: 10.1172/JCI41356.
185. Matthys, A., Haegeman, G., Van Craenenbroeck, K., and Vanhoenacker, P. (2011). Role of the 5-HT7 receptor in the central nervous system: from current status to future perspectives. Mol. Neurobiol. 43, 228-253. doi: 10.1007/s12035-011-8175-3.
186. McCauley, M. D., Wang, T., Mike, E., Herrera, J., Beavers, D. L., Huang, T. W., et al. (2011). Pathogenesis of lethal cardiac arrhythmias in Mecp2 mutant mice: implication for therapy in Rett syndrome. Sci. Transl. Med.3:113ra125. doi: 10.1126/scitranslmed.3002982.
187. McCoy, P. A., and McMahon, L. L. (2007). Muscarinic receptor dependent long-term depression in rat visual cortex is PKC independent but requires ERK1/2 activation and protein synthesis. J. Neurophysiol. 98, 1862-1870. doi: 10.1152/jn.00510.2007.
188. McEwen, B. S., Chattarji, S., Diamond, D. M., Jay, T. M., Reagan, L. P., Svenningsson, P., et al. (2010). The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation. Mol. Psychiatry 15, 237-249. doi: 10.1038/mp.2009.80.
189. Medrihan, L., Tantalaki, E., Aramuni, G., Sargsyan, V., Dudanova, I., Missler, M., et al. (2008). Early defects of GABAergic synapses in the brain stem of a MeCP2 mouse model of Rett syndrome. J. Neurophysiol. 99, 112-121. doi: 10.1152/jn.00826.2007.
190. Mefford, H. C., Batshaw, M. L., and Hoffman, E. P. (2012). Genomics, intellectual disability and autism. N. Engl. J. Med. 366, 733-743. doi: 10.1056/NEJMra1114194.
191. Meyer-Lindenberg, A., Domes, G., Kirsch, P., and Heinrichs, M. (2011). Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nat. Rev. Neurosci. 12, 524-538. doi: 10.1038/nrn3044.
192. Michalon, A., Bruns, A., Risterucci, C., Honer, M., Ballard, T. M., Ozmen, L., et al. (2014). Chronic metabotropic glutamate receptor 5 inhibition corrects local alterations of brain activity and improves cognitive performance in fragile X mice. Biol. Psychiatry 75, 189-197. doi: 10.1016/j.biopsych.2013.05.038.
193. Michalon, A., Sidorov, M., Ballard, T. M., Ozmen, L., Spooren, W., Wettstein, J. G., et al. (2012). Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron 74, 49-56. doi: 10.1016/j.neuron.2012.03.009.
194. Min, W. W., Yuskaitis, C. J., Yan, Q., Sikorski, C., Chen, S., Jope, R. S., et al. (2009). Elevated glycogen synthase kinase-3 activity in fragile X mice: key metabolic regulator with evidence for treatment potential.Neuropharmacology 56, 463-472. doi: 10.1016/j.neuropharm.2008.09.017.
195. Mines, M. A., and Jope, R. S. (2011). Glycogen synthase kinase-3: a promising therapeutic target for fragile x syndrome. Front. Mol. Neurosci. 4:35. doi: 10.3389/fnmol.2011.00035.
196. Mines, M. A., Yuskaitis, C. J., King, M. K., Beurel, E., and Jope, R. S. (2010). GSK3 influences social preference and anxiety-related behaviors during social interaction in a mouse model of fragile X syndrome and autism. PLoS One5:e9706. doi: 10.1371/journal.pone.0009706.
197. Misonou, H. (2010). Homeostatic regulation of neuronal excitability by K(+) channels in normal and diseased brains. Neuroscientist 16, 51-64. doi: 10.1177/1073858409341085.
198. Moretti, P., and Zoghbi, H. Y. (2006). MeCP2 dysfunction in Rett syndrome and related disorders. Curr. Opin. Genet. Dev. 16, 276-281. doi: 10.1016/j.gde.2006.04.009.
199. Mukherjee, S., and Manahan-Vaughan, D. (2013). Role of metabotropic glutamate receptors in persistent forms of hippocampal plasticity and learning. Neuropharmacology 66, 65-81. doi: 10.1016/j.neuropharm.2012.06.005.
200. Murata, Y., and Constantine-Paton, M. (2013). Postsynaptic density scaffold SAP102 regulates cortical synapse development through EphB and PAK signaling pathway. J. Neurosci. 33, 5040-5052. doi: 10.1523/jneurosci.2896-12.2013.
201. Murdoch, J. D., and State, M. W. (2013). Recent developments in the genetics of autism spectrum disorders. Curr. Opin. Genet. Dev. 23, 310-315. doi: 10.1016/j.gde.2013.02.003.
202. Nakamoto, M., Nalavadi, V., Epstein, M. P., Narayanan, U., Bassell, G. J., and Warren, S. T. (2007). Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors. Proc. Natl. Acad. Sci. U S A 104, 15537-15542. doi: 10.1073/pnas.0707484104.
203. Nalivaeva, N. N., and Turner, A. J. (2013). The amyloid precursor protein: a biochemical enigma in brain development, function and disease. FEBS Lett. 587, 2046-2054. doi: 10.1016/j.febslet.2013.05.010.
204. Nan, X., Ng, H. H., Johnson, C. A., Laherty, C. D., Turner, B. M., Eisenman, R. N., et al. (1998). Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393, 386-389. doi: 10.3410/f.718020287.793478774.
205. Narayanan, U., Nalavadi, V., Nakamoto, M., Thomas, G., Ceman, S., Bassell, G. J., et al. (2008). S6K1 phosphorylates and regulates fragile X mental retardation protein (FMRP) with the neuronal protein synthesis-dependent mammalian target of rapamycin (mTOR) signaling cascade. J. Biol. Chem. 283, 18478-18482. doi: 10.1074/jbc.c800055200.
206. Neul, J. L., Kaufmann, W. E., Glaze, D. G., Christodoulou, J., Clarke, A. J., Bahi-Buisson, N., et al. (2010). Rett syndrome: revised diagnostic criteria and nomenclature. Ann. Neurol. 68, 944-950. doi: 10.1002/ana.22124.
207. Neul, J. L., Lane, J. B., Lee, H. S., Geerts, S., Barrish, J. O., Annese, F., et al. (2014). Developmental delay in Rett syndrome: data from the natural history study. J. Neurodev. Disord. 6:20. doi: 10.1186/1866-1955-6-20.
208. Neumann, I. D. (2008). Brain oxytocin: a key regulator of emotional and social behaviours in both females and males. J. Neuroendocrinol. 20, 858-865. doi: 10.1111/j.1365-2826.2008.01726.x.
209. Neumann, I. D., and Landgraf, R. (2012). Balance of brain oxytocin and vasopressin: implications for anxiety, depression and social behaviors. Trends Neurosci. 35, 649-659. doi: 10.1016/j.tins.2012.08.004.
210. Niederhofer, H. (2007). Glutamate antagonists seem to be slightly effective in psychopharmacologic treatment of autism. J. Clin. Psychopharmacol. 27, 317-318. doi: 10.1097/01.jcp.0000270082.30500.69.
211. Ogier, M., Wang, H., Hong, E., Wang, Q., Greenberg, M. E., and Katz, D. M. (2007). Brain-derived neurotrophic factor expression and respiratory function improve after ampakine treatment in a mouse model of Rett syndrome.J. Neurosci. 27, 10912-10917. doi: 10.1523/jneurosci.1869-07.2007.
212. Olmos-Serrano, J. L., Corbin, J. G., and Burns, M. P. (2011). The GABA(A) receptor agonist THIP ameliorates specific behavioral deficits in the mouse model of fragile X syndrome. Dev. Neurosci. 33, 395-403. doi: 10.1159/000332884.
213. Olmos-Serrano, J. L., Paluszkiewicz, S. M., Martin, B. S., Kaufmann, W. E., Corbin, J. G., and Huntsman, M. M. (2010). Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome. J. Neurosci. 30, 9929-9938. doi: 10.1523/jneurosci.1714-10.2010.
214. O’Neill, M. J., Bleakman, D., Zimmerman, D. M., and Nisenbaum, E. S. (2004). AMPA receptor potentiators for the treatment of CNS disorders. Curr. Drug Targets CNS Neurol. Disord. 3, 181-194. doi: 10.2174/1568007043337508.
215. O’Neill, M. J., and Witkin, J. M. (2007). AMPA receptor potentiators: application for depression and Parkinson’s disease. Curr. Drug Targets 8, 603-620. doi: 10.2174/138945007780618517.
216. Osterweil, E. K., Chuang, S. C., Chubykin, A. A., Sidorov, M., Bianchi, R., Wong, R. K., et al. (2013). Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome. Neuron77, 243-250. doi: 10.1016/j.neuron.2012.01.034.
217. Osterweil, E. K., Krueger, D. D., Reinhold, K., and Bear, M. F. (2010). Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome. J. Neurosci. 30, 15616-15627. doi: 10.1523/jneurosci.3888-10.2010.
218. Oudin, M. J., Hobbs, C., and Doherty, P. (2011). DAGL-dependent endocannabinoid signalling: roles in axonal pathfinding, synaptic plasticity and adult neurogenesis. Eur. J. Neurosci. 34, 1634-1646. doi: 10.1111/j.1460-9568.2011.07831.x.
219. Pacey, L. K., and Doering, L. C. (2007). Developmental expression of FMRP in the astrocyte lineage: implications for fragile X syndrome. Glia 55, 1601-1609. doi: 10.1002/glia.20573.
220. Pacey, L. K., Heximer, S. P., and Hampson, D. R. (2009). Increased GABA(B) receptor-mediated signaling reduces the susceptibility of fragile X knockout mice to audiogenic seizures. Mol. Pharmacol. 76, 18-24. doi: 10.1124/mol.109.056127.
221. Pacey, L. K., Tharmalingam, S., and Hampson, D. R. (2011). Subchronic administration and combination metabotropic glutamate and GABAB receptor drug therapy in fragile X syndrome. J. Pharmacol. Exp. Ther. 338, 897-905. doi: 10.1124/jpet.111.183327.
222. Paluszkiewicz, S. M., Martin, B. S., and Huntsman, M. M. (2011). Fragile X syndrome: the GABAergic system and circuit dysfunction. Dev. Neurosci. 33, 349-364. doi: 10.1159/000329420.
223. Paribello, C., Tao, L., Folino, A., Berry-Kravis, E., Tranfaglia, M., Ethell, I. M., et al. (2010). Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol. 10:91. doi: 10.1186/1471-2377-10-91.
224. Paul, K., Venkitaramani, D. V., and Cox, C. L. (2013). Dampened dopamine-mediated neuromodulation in prefrontal cortex of fragile X mice. J. Physiol. 591, 1133-1143. doi: 10.1113/jphysiol.2012.241067.
225. Penagarikano, O., Mulle, J. G., and Warren, S. T. (2007). The pathophysiology of fragile x syndrome. Annu. Rev. Genomics Hum. Genet. 8, 109-129. doi: 10.1146/annurev.genom.8.080706.092249.
226. Percy, A. K., Lane, J. B., Childers, J., Skinner, S., Annese, F., Barrish, J., et al. (2007). Rett syndrome: North American database. J. Child Neurol. 22, 1338-1341. doi: 10.1177/0883073807308715.
227. Percy, A. K., Neul, J. L., Glaze, D. G., Motil, K. J., Skinner, S. A., Khwaja, O., et al. (2010). Rett syndrome diagnostic criteria: lessons from the natural history study. Ann. Neurol. 68, 951-955. doi: 10.1002/ana.22154.
228. Picciotto, M. R., Higley, M. J., and Mineur, Y. S. (2012). Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior. Neuron 76, 116-129. doi: 10.1016/j.neuron.2012.08.036.
229. Pilpel, Y., Kolleker, A., Berberich, S., Ginger, M., Frick, A., Mientjes, E., et al. (2009). Synaptic ionotropic glutamate receptors and plasticity are developmentally altered in the CA1 field of Fmr1 knockout mice. J. Physiol. 587, 787-804. doi: 10.1113/jphysiol.2008.160929.
230. Pitcher, M. R., Ward, C. S., Arvide, E. M., Chapleau, C. A., Pozzo-Miller, L., Hoeflich, A., et al. (2013). Insulinotropic treatments exacerbate metabolic syndrome in mice lacking MeCP2 function. Hum. Mol. Genet. 22, 2626-2633. doi: 10.1093/hmg/ddt111.
231. Pop, A. S., Levenga, J., de Esch, C. E., Buijsen, R. A., Nieuwenhuizen, I. M., Li, T., et al. (2014). Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056/Mavoglurant. Psychopharmacology (Berl)231, 1227-1235. doi: 10.1007/s00213-012-2947-y.
232. Popescu, A. C., Sidorova, E., Zhang, G., and Eubanks, J. H. (2010). Aminoglycoside-mediated partial suppression of MECP2 nonsense mutations responsible for Rett syndrome in vitro. J. Neurosci. Res. 88, 2316-2324. doi: 10.1002/jnr.22409.
233. Prasad, H. C., Steiner, J. A., Sutcliffe, J. S., and Blakely, R. D. (2009). Enhanced activity of human serotonin transporter variants associated with autism. Philos. Trans. R. Soc. Lond. B Biol. Sci. 364, 163-173. doi: 10.1098/rstb.2008.0143.
234. Preti, A., Melis, M., Siddi, S., Vellante, M., Doneddu, G., and Fadda, R. (2014). Oxytocin and autism: a systematic review of randomized controlled trials. J. Child Adolesc. Psychopharmacol. 24, 54-68. doi: 10.1089/cap.2013.0040.
235. Randall, A. D., Witton, J., Booth, C., Hynes-Allen, A., and Brown, J. T. (2010). The functional neurophysiology of the amyloid precursor protein (APP) processing pathway. Neuropharmacology 59, 243-267. doi: 10.1016/j.neuropharm.2010.02.011.
236. Raymond, C. R., Thompson, V. L., Tate, W. P., and Abraham, W. C. (2000). Metabotropic glutamate receptors trigger homosynaptic protein synthesis to prolong long-term potentiation. J. Neurosci. 20, 969-976..
237. Roberts, J. E., Symons, F. J., Johnson, A. M., Hatton, D. D., and Boccia, M. L. (2005). Blink rate in boys with fragile X syndrome: preliminary evidence for altered dopamine function. J. Intellect. Disabil. Res. 49, 647-656. doi: 10.1111/j.1365-2788.2005.00713.x.
238. Rogers, T. D., Dickson, P. E., McKimm, E., Heck, D. H., Goldowitz, D., Blaha, C. D., et al. (2013). Reorganization of circuits underlying cerebellar modulation of prefrontal cortical dopamine in mouse models of autism spectrum disorder. Cerebellum 12, 547-556. doi: 10.1007/s12311-013-0462-2.
239. Ronemus, M., Iossifov, I., Levy, D., and Wigler, M. (2014). The role of de novo mutations in the genetics of autism spectrum disorders. Nat. Rev. Genet. 15, 133-141. doi: 10.1038/nrg3585.
240. Ronesi, J. A., and Huber, K. M. (2008a). Metabotropic glutamate receptors and fragile x mental retardation protein: partners in translational regulation at the synapse. Sci. Signal. 1:pe6. doi: 10.1126/stke.15pe6.
241. Ronesi, J. A., and Huber, K. M. (2008b). Homer interactions are necessary for metabotropic glutamate receptor-induced long-term depression and translational activation. J. Neurosci. 28, 543-547. doi: 10.1523/jneurosci.5019-07.2008.
242. Rotschafer, S. E., Trujillo, M. S., Dansie, L. E., Ethell, I. M., and Razak, K. A. (2012). Minocycline treatment reverses ultrasonic vocalization production deficit in a mouse model of Fragile X syndrome. Brain Res. 1439, 7-14. doi: 10.1016/j.brainres.2011.12.041.
243. Roux, J. C., Dura, E., Moncla, A., Mancini, J., and Villard, L. (2007). Treatment with desipramine improves breathing and survival in a mouse model for Rett syndrome. Eur. J. Neurosci. 25, 1915-1922. doi: 10.1111/j.1460-9568.2007.05466.x.
244. Roux, J. C., Dura, E., and Villard, L. (2008). Tyrosine hydroxylase deficit in the chemoafferent and the sympathoadrenergic pathways of the Mecp2 deficient mouse. Neurosci. Lett. 447, 82-86. doi: 10.1016/j.neulet.2008.09.045.
245. Samaco, R. C., and Neul, J. L. (2011). Complexities of Rett syndrome and MeCP2. J. Neurosci. 31, 7951-7959. doi: 10.1523/jneurosci.0169-11.2011.
246. Santoro, M. R., Bray, S. M., and Warren, S. T. (2012). Molecular mechanisms of fragile X syndrome: a twenty-year perspective. Annu. Rev. Pathol. 7, 219-245. doi: 10.1146/annurev-pathol-011811-132457.
247. Schanen, C., Houwink, E. J., Dorrani, N., Lane, J., Everett, R., Feng, A., et al. (2004). Phenotypic manifestations of MECP2 mutations in classical and atypical Rett syndrome. Am. J. Med. Genet. A 126A, 129-140. doi: 10.1002/ajmg.a.20571.
248. Scheele, D., Kendrick, K. M., Khouri, C., Kretzer, E., Schläpfer, T. E., Stoffel-Wagner, B., et al. (2014). An oxytocin-induced facilitation of neural and emotional responses to social touch correlates inversely with autism traits.Neuropsychopharmacology 39, 2078-2085. doi: 10.1038/npp.2014.78.
249. Schmid, D. A., Yang, T., Ogier, M., Adams, I., Mirakhur, Y., Wang, Q., et al. (2012). A TrkB small molecule partial agonist rescues TrkB phosphorylation deficits and improves respiratory function in a mouse model of Rett syndrome. J. Neurosci. 32, 1803-1810. doi: 10.1523/JNEUROSCI.0865-11.2012.
250. Schmit, T. L., Dowell, J. A., Maes, M. E., and Wilhelm, M. (2013). c-Jun N-terminal kinase regulates mGluR-dependent expression of post-synaptic FMRP target proteins. J. Neurochem. 127, 772-781. doi: 10.1111/jnc.12453.
251. Seamans, J. K., and Yang, C. R. (2004). The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog. Neurobiol. 74, 1-58. doi: 10.1016/j.pneurobio.2004.05.006.
252. Segal, R. A., and Greenberg, M. E. (1996). Intracellular signaling pathways activated by neurotrophic factors. Annu. Rev. Neurosci. 19, 463-489. doi: 10.1146/annurev.neuro.19.1.463.
253. Shahbazian, M. D., Antalffy, B., Armstrong, D. L., and Zoghbi, H. Y. (2002). Insight into Rett syndrome: MeCP2 levels display tissue- and cell-specific differences and correlate with neuronal maturation. Hum. Mol. Genet. 11, 115-124. doi: 10.1093/hmg/11.2.115.
254. Sharma, A., Hoeffer, C. A., Takayasu, Y., Miyawaki, T., McBride, S. M., Klann, E., et al. (2010). Dysregulation of mTOR signaling in fragile X syndrome. J. Neurosci. 30, 694-702. doi: 10.1523/jneurosci.3696-09.2010.
255. Sidhu, H., Dansie, L. E., Hickmott, P. W., Ethell, D. W., and Ethell, I. M. (2014). Genetic removal of matrix metalloproteinase 9 rescues the symptoms of fragile x syndrome in a mouse model. J. Neurosci. 34, 9867-9879. doi: 10.1523/jneurosci.1162-14.2014.
256. Sidorov, M. S., Auerbach, B. D., and Bear, M. F. (2013). Fragile X mental retardation protein and synaptic plasticity.Mol. Brain 6:15. doi: 10.1186/1756-6606-6-15.
257. Sigel, E., and Steinmann, M. E. (2012). Structure, function and modulation of GABA(A) receptors. J. Biol. Chem.287, 40224-40231. doi: 10.1074/jbc.R112.386664.
258. Siller, S. S., and Broadie, K. (2012). Matrix metalloproteinases and minocycline: therapeutic avenues for fragile X syndrome. Neural Plast. 2012:124548. doi: 10.1155/2012/124548.
259. Straiker, A., Min, K. T., and Mackie, K. (2013). Fmr1 deletion enhances and ultimately desensitizes CB(1) signaling in autaptic hippocampal neurons. Neurobiol. Dis. 56, 1-5. doi: 10.1016/j.nbd.2013.04.002.
260. Strumbos, J. G., Brown, M. R., Kronengold, J., Polley, D. B., and Kaczmarek, L. K. (2010). Fragile X mental retardation protein is required for rapid experience-dependent regulation of the potassium channel Kv3.1b. J. Neurosci. 30, 10263-10271. doi: 10.1523/jneurosci.1125-10.2010.
261. Sugden, P. H., Fuller, S. J., Weiss, S. C., and Clerk, A. (2008). Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis. Br. J. Pharmacol. 153(Suppl 1), S137-S153. doi: 10.1038/sj.bjp.0707659.
262. Surmeier, D. J., Plotkin, J., and Shen, W. (2009). Dopamine and synaptic plasticity in dorsal striatal circuits controlling action selection. Curr. Opin. Neurobiol. 19, 621-628. doi: 10.1016/j.conb.2009.10.003.
263. Suvrathan, A., Hoeffer, C. A., Wong, H., Klann, E., and Chattarji, S. (2010). Characterization and reversal of synaptic defects in the amygdala in a mouse model of fragile X syndrome. Proc. Natl. Acad. Sci. U S A 107, 11591-11596. doi: 10.1073/pnas.1002262107.
264. Tavoulari, S., Forrest, L. R., and Rudnick, G. (2009). Fluoxetine (Prozac) binding to serotonin transporter is modulated by chloride and conformational changes. J. Neurosci. 29, 9635-9643. doi: 10.1523/jneurosci.0440-09.2009.
265. Thomas, A. M., Bui, N., Graham, D., Perkins, J. R., Yuva-Paylor, L. A., and Paylor, R. (2011). Genetic reduction of group 1 metabotropic glutamate receptors alters select behaviors in a mouse model for fragile X syndrome. Behav. Brain Res. 223, 310-321. doi: 10.1016/j.bbr.2011.04.049.
266. Thomas, A. M., Bui, N., Perkins, J. R., Yuva-Paylor, L. A., and Paylor, R. (2012). Group I metabotropic glutamate receptor antagonists alter select behaviors in a mouse model for fragile X syndrome. Psychopharmacology (Berl)219, 47-58. doi: 10.1007/s00213-011-2375-4.
267. Thomas, G. M., and Huganir, R. L. (2004). MAPK cascade signalling and synaptic plasticity. Nat. Rev. Neurosci. 5, 173-183. doi: 10.1038/nrn1346.
268. Trappe, R., Laccone, F., Cobilanschi, J., Meins, M., Huppke, P., Hanefeld, F., et al. (2001). MECP2 mutations in sporadic cases of Rett syndrome are almost exclusively of paternal origin. Am. J. Hum. Genet. 68, 1093-1101. doi: 10.1086/320109.
269. Tropea, D., Giacometti, E., Wilson, N. R., Beard, C., McCurry, C., Fu, D. D., et al. (2009). Partial reversal of Rett syndrome-like symptoms in MeCP2 mutant mice. Proc. Natl. Acad. Sci. U S A 106, 2029-2034. doi: 10.1073/pnas.0812394106.
270. Tyzio, R., Nardou, R., Ferrari, D. C., Tsintsadze, T., Shahrokhi, A., Eftekhari, S., et al. (2014). Oxytocin-mediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring. Science 343, 675-679. doi: 10.1126/science.1247190.
271. Upreti, C., Zhang, X. L., Alford, S., and Stanton, P. K. (2013). Role of presynaptic metabotropic glutamate receptors in the induction of long-term synaptic plasticity of vesicular release. Neuropharmacology 66, 31-39. doi: 10.1016/j.neuropharm.2012.05.004.
272. Uutela, M., Lindholm, J., Rantamäki, T., Umemori, J., Hunter, K., Võikar, V., et al. (2014). Distinctive behavioral and cellular responses to fluoxetine in the mouse model for fragile X syndrome. Front. Cell. Neurosci. 8:150. doi: 10.3389/fncel.2014.00150.
273. Veenstra-VanderWeele, J., Muller, C. L., Iwamoto, H., Sauer, J. E., Owens, W. A., Shah, C. R., et al. (2012). Autism gene variant causes hyperserotonemia, serotonin receptor hypersensitivity, social impairment and repetitive behavior. Proc. Natl. Acad. Sci. U S A 109, 5469-5474. doi: 10.1073/pnas.1112345109.
274. Veeraragavan, S., Bui, N., Perkins, J. R., Yuva-Paylor, L. A., Carpenter, R. L., and Paylor, R. (2011b). Modulation of behavioral phenotypes by a muscarinic M1 antagonist in a mouse model of fragile X syndrome.Psychopharmacology (Berl) 217, 143-151. doi: 10.1007/s00213-011-2276-6.
275. Veeraragavan, S., Bui, N., Perkins, J. R., Yuva-Paylor, L. A., and Paylor, R. (2011a). The modulation of fragile X behaviors by the muscarinic M4 antagonist, tropicamide. Behav. Neurosci. 125, 783-790. doi: 10.1037/a0025202.
276. Veeraragavan, S., Graham, D., Bui, N., Yuva-Paylor, L. A., Wess, J., and Paylor, R. (2012). Genetic reduction of muscarinic M4 receptor modulates analgesic response and acoustic startle response in a mouse model of fragile X syndrome (FXS). Behav. Brain Res. 228, 1-8. doi: 10.1016/j.bbr.2011.11.018.
277. Vinueza Veloz, M. F., Buijsen, R. A., Willemsen, R., Cupido, A., Bosman, L. W., Koekkoek, S. K., et al. (2012). The effect of an mGluR5 inhibitor on procedural memory and avoidance discrimination impairments in Fmr1 KO mice.Genes Brain Behav. 11, 325-331. doi: 10.1111/j.1601-183x.2011.00763.x.
278. Volk, L. J., Pfeiffer, B. E., Gibson, J. R., and Huber, K. M. (2007). Multiple Gq-coupled receptors converge on a common protein synthesis-dependent long-term depression that is affected in fragile X syndrome mental retardation. J. Neurosci. 27, 11624-11634. doi: 10.1523/jneurosci.2266-07.2007.
279. Volpicelli, L. A., and Levey, A. I. (2004). Muscarinic acetylcholine receptor subtypes in cerebral cortex and hippocampus. Prog. Brain Res. 145, 59-66. doi: 10.1016/s0079-6123(03)45003-6.
280. Wang, H. (2014). Lipid rafts: a signaling platform linking cholesterol metabolism to synaptic deficits in autism spectrum disorders. Front. Behav. Neurosci. 8:104. doi: 10.3389/fnbeh.2014.00104.
281. Wang, L. W., Berry-Kravis, E., and Hagerman, R. J. (2010b). Fragile X: leading the way for targeted treatments in autism. Neurotherapeutics 7, 264-274. doi: 10.1016/j.nurt.2010.05.005.
282. Wang, T., Bray, S. M., and Warren, S. T. (2012a). New perspectives on the biology of fragile X syndrome. Curr. Opin. Genet. Dev. 22, 256-263. doi: 10.1016/j.gde.2012.02.002.
283. Wang, H., and Doering, L. C. (2012). Induced pluripotent stem cells to model and treat neurogenetic disorders.Neural Plast. 2012:346053. doi: 10.1155/2012/346053.
284. Wang, H., and Doering, L. C. (2013). Reversing autism by targeting downstream mTOR signaling. Front. Cell. Neurosci. 7:28. doi: 10.3389/fncel.2013.00028.
285. Wang, H., Kim, S. S., and Zhuo, M. (2010a). Roles of fragile X mental retardation protein in dopaminergic stimulation-induced synapse-associated protein synthesis and subsequent alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-4-propionate (AMPA) receptor internalization. J. Biol. Chem. 285, 21888-21901. doi: 10.1074/jbc.M110.116293.
286. Wang, H., Ku, L., Osterhout, D. J., Li, W., Ahmadian, A., Liang, Z., et al. (2004). Developmentally-programmed FMRP expression in oligodendrocytes: a potential role of FMRP in regulating translation in oligodendroglia progenitors. Hum. Mol. Genet. 13, 79-89. doi: 10.1093/hmg/ddh009.
287. Wang, G. X., Smith, S. J., and Mourrain, P. (2014). Fmr1 KO and fenobam treatment differentially impact distinct synapse populations of mouse neocortex. Neuron 84, 1273-1286. doi: 10.1016/j.neuron.2014.11.016.
288. Wang, X., Snape, M., Klann, E., Stone, J. G., Singh, A., Petersen, R. B., et al. (2012b). Activation of the extracellular signal-regulated kinase pathway contributes to the behavioral deficit of fragile x-syndrome. J. Neurochem. 121, 672-679. doi: 10.1111/j.1471-4159.2012.07722.x.
289. Wang, H., Wu, L. J., Kim, S. S., Lee, F. J., Gong, B., Toyoda, H., et al. (2008b). FMRP acts as a key messenger for dopamine modulation in the forebrain. Neuron 59, 634-647. doi: 10.1016/j.neuron.2008.06.027.
290. Wang, H., Wu, L. J., Zhang, F., and Zhuo, M. (2008a). Roles of calcium-stimulated adenylyl cyclase and calmodulin-dependent protein kinase IV in the regulation of FMRP by group I metabotropic glutamate receptors. J. Neurosci.28, 4385-4397. doi: 10.1523/JNEUROSCI.0646-08.2008.
291. Wang, H., and Zhuo, M. (2012). Group I metabotropic glutamate receptor-mediated gene transcription and implications for synaptic plasticity and diseases. Front. Pharmacol. 3:189. doi: 10.3389/fphar.2012.00189.
292. Watanabe, T., Abe, O., Kuwabara, H., Yahata, N., Takano, Y., Iwashiro, N., et al. (2014). Mitigation of sociocommunicational deficits of autism through oxytocin-induced recovery of medial prefrontal activity: a randomized trial. JAMA Psychiatry 71, 166-175. doi: 10.1001/jamapsychiatry.2013.3181.
293. Wei, H., Dobkin, C., Sheikh, A. M., Malik, M., Brown, W. T., and Li, X. (2012). The therapeutic effect of memantine through the stimulation of synapse formation and dendritic spine maturation in autism and fragile X syndrome.PLoS One 7:e36981. doi: 10.1371/journal.pone.0036981.
294. Weiler, I. J., and Greenough, W. T. (1993). Metabotropic glutamate receptors trigger postsynaptic protein synthesis. Proc. Natl. Acad. Sci. U S A 90, 7168-7171. doi: 10.1073/pnas.90.15.7168.
295. Weinshenker, D., and Warren, S. T. (2008). Neuroscience: fragile dopamine. Nature 455, 607-608. doi: 10.1038/455607a.
296. Weng, N., Weiler, I. J., Sumis, A., Berry-Kravis, E., and Greenough, W. T. (2008). Early-phase ERK activation as a biomarker for metabolic status in fragile X syndrome. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147B, 1253-1257. doi: 10.1002/ajmg.b.30765.
297. Wernicke, J. F. (2004). Safety and side effect profile of fluoxetine. Expert Opin. Drug Saf. 3, 495-504. doi: 10.1517/14740338.3.5.495.
298. Westmark, C. J. (2013). What’s hAPPening at synapses? The role of amyloid beta-protein precursor and β-amyloid in neurological disorders. Mol. Psychiatry 18, 425-434. doi: 10.1038/mp.2012.122.
299. Westmark, C. J., Berry-Kravis, E. M., Ikonomidou, C., Yin, J. C., and Puglielli, L. (2013). Developing BACE-1 inhibitors for FXS. Front. Cell. Neurosci. 7:77. doi: 10.3389/fncel.2013.00077.
300. Westmark, C. J., and Malter, J. S. (2007). FMRP mediates mGluR5-dependent translation of amyloid precursor protein. PLoS Biol. 5:e52. doi: 10.1371/journal.pbio.0050052.
301. Westmark, C. J., Westmark, P. R., and Malter, J. S. (2010). MPEP reduces seizure severity in Fmr-1 KO mice over expressing human Abeta. Int. J. Clin. Exp. Pathol. 3, 56-68..
302. Westmark, C. J., Westmark, P. R., O’Riordan, K. J., Ray, B. C., Hervey, C. M., Salamat, M. S., et al. (2011). Reversal of fragile X phenotypes by manipulation of AβPP/Aβ levels in Fmr1KO mice. PLoS One 6:e26549. doi: 10.1371/journal.pone.0026549.
303. Wiegert, J. S., and Bading, H. (2011). Activity-dependent calcium signaling and ERK-MAP kinases in neurons: a link to structural plasticity of the nucleus and gene transcription regulation. Cell Calcium 49, 296-305. doi: 10.1016/j.ceca.2010.11.009.
304. Wijetunge, L. S., Chattarji, S., Wyllie, D. J., and Kind, P. C. (2013). Fragile X syndrome: from targets to treatments.Neuropharmacology 68, 83-96. doi: 10.1016/j.neuropharm.2012.11.028.
305. Wong, D. T., Perry, K. W., and Bymaster, F. P. (2005). Case history: the discovery of fluoxetine hydrochloride (Prozac). Nat. Rev. Drug Discov. 4, 764-774. doi: 10.1038/nrd1821.
306. Wright, J. W., and Harding, J. W. (2009). Contributions of matrix metalloproteinases to neural plasticity, habituation, associative learning and drug addiction. Neural Plast. 2009:579382. doi: 10.1155/2009/579382.
307. Yan, Q. J., Rammal, M., Tranfaglia, M., and Bauchwitz, R. P. (2005). Suppression of two major fragile X syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 49, 1053-1066. doi: 10.1016/j.neuropharm.2005.06.004.
308. Yun, S. H., and Trommer, B. L. (2011). Fragile X mice: reduced long-term potentiation and N-Methyl-D-Aspartate receptor-mediated neurotransmission in dentate gyrus. J. Neurosci. Res. 89, 176-182. doi: 10.1002/jnr.22546.
309. Yuskaitis, C. J., Mines, M. A., King, M. K., Sweatt, J. D., Miller, C. A., and Jope, R. S. (2010). Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome. Biochem. Pharmacol. 79, 632-646. doi: 10.1016/j.bcp.2009.09.023.
310. Zanella, S., Mebarek, S., Lajard, A. M., Picard, N., Dutschmann, M., and Hilaire, G. (2008). Oral treatment with desipramine improves breathing and life span in Rett syndrome mouse model. Respir. Physiol. Neurobiol. 160, 116-121. doi: 10.1016/j.resp.2007.08.009.
311. Zhang, L., and Alger, B. E. (2010). Enhanced endocannabinoid signaling elevates neuronal excitability in fragile X syndrome. J. Neurosci. 30, 5724-5729. doi: 10.1523/JNEUROSCI.0795-10.2010.
312. Zhang, Y., Bonnan, A., Bony, G., Ferezou, I., Pietropaolo, S., Ginger, M., et al. (2014b). Dendritic channelopathies contribute to neocortical and sensory hyperexcitability in Fmr1(-/y) mice. Nat. Neurosci. 17, 1701-1709. doi: 10.1038/nn.3864.
313. Zhang, Y., Brown, M. R., Hyland, C., Chen, Y., Kronengold, J., Fleming, M. R., et al. (2012). Regulation of neuronal excitability by interaction of fragile X mental retardation protein with slack potassium channels. J. Neurosci. 32, 15318-15327. doi: 10.1523/JNEUROSCI.2162-12.2012.
314. Zhang, W., Peterson, M., Beyer, B., Frankel, W. N., and Zhang, Z. W. (2014a). Loss of MeCP2 from forebrain excitatory neurons leads to cortical hyperexcitation and seizures. J. Neurosci. 34, 2754-2763. doi: 10.1523/JNEUROSCI.4900-12.2014.
315. Zhang, Y., Venkitaramani, D. V., Gladding, C. M., Kurup, P., Molnar, E., Collingridge, G. L., et al. (2008). The tyrosine phosphatase STEP mediates AMPA receptor endocytosis after metabotropic glutamate receptor stimulation. J. Neurosci. 28, 10561-10566. doi: 10.1523/JNEUROSCI.2666-08.2008.
316. Zhang, H., Webb, D. J., Asmussen, H., Niu, S., and Horwitz, A. F. (2005). A GIT1/PIX/Rac/PAK signaling module regulates spine morphogenesis and synapse formation through MLC. J. Neurosci. 25, 3379-3388. doi: 10.1523/jneurosci.3553-04.2005.
317. Zhang, Z. W., Zak, J. D., and Liu, H. (2010). MeCP2 is required for normal development of GABAergic circuits in the thalamus. J. Neurophysiol. 103, 2470-2481. doi: 10.1152/jn.00601.2009.
318. Zheng, W. H., and Quirion, R. (2004). Comparative signaling pathways of insulin-like growth factor-1 and brain-derived neurotrophic factor in hippocampal neurons and the role of the PI3 kinase pathway in cell survival. J. Neurochem. 89, 844-852. doi: 10.1111/j.1471-4159.2004.02350.x.
319. Ziemssen, T., Kümpfel, T., Klinkert, W. E., Neuhaus, O., and Hohlfeld, R. (2002). Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain 125, 2381-2391. doi: 10.1093/brain/awf252.
320. Zingman, L. V., Park, S., Olson, T. M., Alekseev, A. E., and Terzic, A. (2007). Aminoglycoside-induced translational read-through in disease: overcoming nonsense mutations by pharmacogenetic therapy. Clin. Pharmacol. Ther. 81, 99-103. doi: 10.1038/sj.clpt.6100012.
321. Zoghbi, H. Y., and Bear, M. F. (2012). Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities. Cold Spring Harb. Perspect. Biol. 4, pii:a009886. doi: 10.1101/cshperspect.a009886.
322. Zupan, B., and Toth, M. (2008). Inactivation of the maternal fragile X gene results in sensitization of GABAB receptor function in the offspring. J. Pharmacol. Exp. Ther. 327, 820-826. doi: 10.1124/jpet.108.143990.